Full View

Evolocumab is initiated in Central and Eastern Europe at much higher LDL-C levels than recommended in guidelines: Results from the observational HEYMANS study

V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - journals.sagepub.com
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
相关文章

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS …

V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - europepmc.org
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …
[PDF] mediamed.ro

[PDF][PDF] Evolocumab is initiated in Central and Eastern Europe at much higher LDL-C levels than recommended in guidelines: Results from the observational …

V Blaha, R Margoczy, I Petrov, A Postadzhiyan… - 2022 - repo.mediamed.ro
• Elevated low-density-lipoprotein cholesterol (LDL-C) is a major risk factor for
cardiovascular disease (CVD) 1, 2• PCSK9 inhibitors are recommended if LDL-C goals are …

Evolocumab is initiated in Central and Eastern Europe at much higher LDL-C levels than recommended in guidelines: Results from the observational HEYMANS study

V Blaha, R Margoczy, I Petrov, A Postadzhiyan… - iscpcardio.org
Objectives: We examined clinical characteristics and LDL-C lowering in patients initiating
evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the …

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS …

V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS …

V Blaha, R Margoczy, I Petrov… - Journal of …, 2023 - search.ebscohost.com
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-
C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern …

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS …

V Blaha, R Margoczy, I Petrov… - European Cardiology …, 2023 - ncbi.nlm.nih.gov
Objective: We examined clinical characteristics and LDL-C lowering in patients initiating
evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the …

27th Annual Meeting of the ISCP

V Blaha, R Margoczy, I Petrov, A Postadzhiyan… - 2023 - assets.radcliffecardiology.com
Objective: We examined clinical characteristics and LDL-C lowering in patients initiating
evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the …

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS …

V Blaha, R Margoczy, I Petrov, A Postadzhiyan… - European …, 2023 - europepmc.org
Objective: We examined clinical characteristics and LDL-C lowering in patients initiating
evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the …

Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS …

V Blaha, R Margoczy, I Petrov… - European …, 2023 - pubmed.ncbi.nlm.nih.gov
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than
Recommended in Guidelines: Results from the Observational HEYMANS Study Evolocumab is …